Leadership Overview
Sarepta Therapeutics has 7 executives leading key functions including information technology, marketing, operations, medical affairs, research and development, and human resources.
Driven by a commitment to innovation, Sarepta Therapeutics is dedicated to discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally.
Driven by a commitment to innovation, Sarepta Therapeutics is dedicated to discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally.
Leadership Roles at Sarepta Therapeutics
Brian Forsa - Vice President, Chief of Staff To Chief Executive Officer
Brian Forsa, the Vice President, Chief of Staff To Chief Executive Officer at Sarepta Therapeutics, provides strategic support and operational coordination for the CEO's office. This critical liaison role involves managing key initiatives, facilitating communication across executive teams, and ensuring alignment with corporate objectives. Forsa's responsibilities include driving strategic projects, preparing executive briefings, and optimizing the CEO's workflow to enhance decision-making and operational effectiveness. The Chief of Staff function ensures that the company's focus on precision genetic medicines for rare diseases remains sharp and that execution aligns with Sarepta's ambitious growth plans. Brian Forsa's leadership ensures seamless operational flow at the highest executive level.
Ian Estepan - President & Chief Operating Officer
Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, directs the company's day-to-day operations and oversees the execution of its strategic business plans. This executive role encompasses managing global operations, supply chain logistics, and ensuring the efficient commercialization of Sarepta's precision genetic medicines. Estepan's leadership focuses on scaling manufacturing capabilities, optimizing distribution networks, and driving operational excellence across all business functions. The Chief Operating Officer ensures that Sarepta's commitment to developing treatments for rare diseases, particularly Duchenne muscular dystrophy, is supported by robust and efficient operational infrastructure. Ian Estepan's oversight is crucial for sustained growth and market leadership.
Louise Rodino-Klapac - President, Research Development & Technical Operations
Louise Rodino-Klapac, the President, Research Development & Technical Operations at Sarepta Therapeutics, spearheads the company's scientific innovation and manufacturing capabilities. This pivotal role drives the discovery and development of novel precision genetic medicines, including gene therapy, RNA-targeted therapeutics, and gene editing modalities. Rodino-Klapac oversees the entire pipeline from early-stage research through to the technical operations required for commercial-scale production. Her leadership ensures that Sarepta's advancements in treating Duchenne muscular dystrophy and other rare neuromuscular and central nervous system disorders are scientifically rigorous and technically sound. Louise Rodino-Klapac's expertise is central to advancing Sarepta's mission to bring transformative therapies to patients globally.
William Thornton - Chief Information Officer
William Thornton, the Chief Information Officer at Sarepta Therapeutics, directs the company's technology strategy and infrastructure. Overseeing all IT operations, Thornton ensures robust systems support Sarepta's global commercial and research endeavors. This leadership role involves managing data security, enhancing digital platforms, and driving technological innovation to accelerate the development and delivery of precision genetic medicines. By optimizing IT resources, Thornton directly contributes to operational efficiency and the secure handling of sensitive research and patient data across North America, Europe, and Asia. The Chief Information Officer's focus remains on scalable technology solutions that align with Sarepta's mission to treat rare diseases.
Farzana Quddus - Principal Engineer & Chief Marketing Officer, Operation
Farzana Quddus, the Principal Engineer & Chief Marketing Officer, Operation at Sarepta Therapeutics, spearheads critical engineering initiatives and oversees operational marketing strategies. This dual role involves driving technical advancements in precision genetic medicine while also shaping the market perception and commercialization of Sarepta's therapies. Quddus's engineering expertise informs operational strategies, ensuring product development aligns with market needs and regulatory requirements. The Chief Marketing Officer, Operation function focuses on translating complex scientific achievements into accessible value propositions for stakeholders across global markets. Farzana Quddus's leadership ensures seamless integration between technical innovation and market execution, supporting Sarepta's mission in Duchenne muscular dystrophy and other rare conditions.
Kirsten M. - Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff
Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, directs the operational execution of global medical affairs strategies. This leadership position involves overseeing program management for critical medical initiatives and ensuring efficient operations across international teams. Kirsten M.'s focus is on streamlining processes for clinical trial support, medical education, and evidence generation, directly impacting the delivery of Sarepta's genetic therapies. The Chief of Staff role within Global Medical Affairs ensures strategic alignment and effective resource allocation. Kirsten M. drives operational excellence, supporting the company's commitment to advancing treatments for neuromuscular and central nervous system disorders worldwide.
Alison Nasisi - Executive Vice President & Chief People Officer
Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, leads all human capital strategies and organizational development initiatives. This executive function focuses on cultivating a high-performance culture, attracting and retaining top talent, and fostering an environment that supports innovation in precision genetic medicine. Nasisi oversees talent acquisition, compensation and benefits, employee relations, and learning and development programs across Sarepta's global operations. The Chief People Officer ensures that Sarepta's workforce is equipped to meet the challenges of developing and commercializing life-changing therapies for rare diseases. Alison Nasisi's strategic leadership in people operations is fundamental to Sarepta's mission and continued success.
Explore Leadership Teams in Manufacturing
Abbott is a global healthcare company that develops and delivers a broad range of medical technologies, diagnostics, nutrition products, and branded generic medicines. The company is focused on improving health outcomes and helping people live healthier lives across all stages of life. Its mission centers on creating innovative solutions that address important medical needs, including chronic disease management, cardiovascular care, diabetes care, and pain management.
Company Leadership AM
AB
JA
HS
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Company Leadership
BB
YK
TK
GC Biopharma Corp., formerly known as Green Cross Corporation, is a South Korean biopharmaceutical company specializing in the development, manufacturing, and distribution of vaccines, plasma-derived therapies, and other pharmaceutical products. Founded in 1967 and headquartered in Yongin, South Korea, GC Biopharma has grown into one of the leading companies in the Korean pharmaceutical industry, with a strong international presence.
Company Leadership FK
SK
JP
KL
Акрихин is a leading Russian pharmaceutical company that has been producing effective, affordable, and high-quality medications since 1936. The company offers a diverse portfolio of over 200 socially significant pharmaceutical products, including prescription and over-the-counter drugs. With a strong focus on research and development, Акрихин actively invests in creating new medications and adheres to international GMP standards in all stages of production. The company aims to serve a wide range of clients, including healthcare professionals and patients in need of reliable medical treatments.
Company Leadership AT
KP
BT
Frequently Asked Questions Regarding Sarepta Therapeutics Top Executives and Leadership Team
Unlock more people and company data
